Semantic and psychometric validation of the Brazilian Portuguese version (PASE-P) of the Psoriatic Arthritis Screening and Evaluation questionnaire

Abstract

PASE (Psoriatic Arthritis Screening and Evaluation) was developed in the English language to screen for inflammatory arthritis among patients with psoriasis. It is 15 item self administered questionnaire with a score from 15 to 75. A higher score indicates a greater risk for inflammatory joint disease. The purpose of this study was to translate, adapt and validate this questionnaire into Brazilian Portuguese (PASE-P). METHODS: 465 patients diagnosed with psoriasis (158 with psoriatic arthritis confirmed by a rheumatologist according to the CASPAR criteria and 307 without) were evaluated in dermatology clinics. We performed the analysis of semantic equivalence in eight steps. For psychometric equivalence, we evaluated the data quality, reliability, construct validity, well-known groups and discriminant characteristics of the items, as well as a ROC curve to determine optimal PASE-P cutoff points in case identification and their sensitivity / specificity. The final version presented excellent reproducibility (CCI = 0.97) and reliability (Cronbach’s alpha> 0.9). A cut-off point of 25 distinguished between patients with and without psoriatic arthritis, with sensitivity of 69.5 and specificity of 86.8. PASE-P proved to be culturally valid and reliable to screen for psoriatic arthritis in Brazilian patients with psoriasis.

Psoriatic arthritis screening: A systematic literature review and experts’ recommendations

“…The main characteristics of the included studies are outlined in Table 1 and the results are presented in Table 2 . Most of the included studies were validation studies [ 13 – 17 , 47 , 50 , 54 , 58 , 64 , 68 , 77 , 78 ], cross-cultural validation studies [ 49 , 51 , 52 , 54 , 59 , 61 – 63 , 71 – 73 ], or diagnostic performance studies [ 10 , 53 , 55 – 57 , 60 , 65 , 67 , 69 , 70 , 74 , 75 , 80 , 81 ]. We also found other designs, including case-control studies [ 48 ], clinical trials [ 66 ], and prospective observational designs [ 79 ].…”

“…The following questionnaire-based tools were included in the present SLR: PEST [ 10 , 14 , 49 , 54 – 57 , 67 , 69 , 73 – 75 , 81 ], PASE [ 10 , 13 , 16 , 49 , 51 , 52 , 55 , 56 , 59 , 60 , 63 , 66 , 67 , 70 , 75 , 79 – 81 ], EARP [ 16 , 49 , 54 , 67 , 71 , 75 , 80 ], ToPAS [ 10 , 15 , 49 , 53 , 55 , 56 , 62 , 74 , 75 , 79 ], ToPAS 2 [ 61 , 78 ], SiPAT (45) [ 54 ], PURE-4 [ 17 ], CONTEST [ 49 , 56 – 58 ], GEPARD [ 65 , 72 ], PASQ [ 50 ,…”

“…The gold standard for PsA diagnosis also varied. The CASPAR criteria were widely used [ 10 , 15 – 17 , 47 – 50 , 52 , 54 , 55 , 58 , 59 , 61 – 63 , 65 , 67 – 73 , 75 , 77 – 79 ], but the Moll and Wright criteria [ 13 , 51 , 60 ], rheumatologist’s criteria [ 14 , 50 , 53 , 56 , 57 , 64 , 74 ], and others were all also employed [ 80 ].…”

“…The AUC of screening tools was higher than 80% in the majority of studies. This was not the case for the following individual studies, which are grouped by PsA screening tool: PASE [ 55 , 58 , 67 , 80 ], PEST [ 55 , 58 , 59 , 67 ], CONTEST [ 59 ], ToPAS [ 55 , 58 ], PASQ [ 14 ], and EARP [ 67 , 80 ].…”

“…The following questionnaire-based tools were included in the present SLR: PEST [10, 14, 49, 54-57, 67, 69, 73-75, 81], PASE [10,13,16,49,51,52,55,56,59,60,63,66,67,70,75,[79][80][81], EARP [16,49,54,67,71,75,80], ToPAS [10,15,49,53,55,56,62,74,75,79], ToPAS 2 [61,78], SiPAT (45) [54], PURE-4 [17], CONTEST [49,[56][57][58], GEPARD [65,72], PASQ [50,74], ePASQ [68], and SiPAS [77]. The number of items included in these questionnaires varied from 4…”